![Tom Boone](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Tom Boone
Fondateur chez REMD Biotherapeutics, Inc.
Postes actifs de Tom Boone
Sociétés | Poste | Début | Fin |
---|---|---|---|
REMD Biotherapeutics, Inc.
![]() REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Directeur Technique/Scientifique/R&D | 01/01/2011 | - |
Fondateur | 01/01/2011 | - | |
Ally Bridge Group HK Ltd
![]() Ally Bridge Group HK Ltd Investment ManagersFinance Ally Bridge Group HK Ltd (Ally Bridge) is a private equity firm founded in 2011 by Frank Yu. The firm is headquartered in Hong Kong with additional office in the US. | Consultant / Advisor | 01/01/2014 | - |
Historique de carrière de Tom Boone
Formation de Tom Boone
University of California, Davis | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 3 |
Hong Kong | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Consultant / Advisor | 1 |
Sectorielle
Health Technology | 2 |
Finance | 2 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
REMD Biotherapeutics, Inc.
![]() REMD Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology REMD Biotherapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing protein-based therapies to treat metabolic diseases and other serious illnesses. The private company was founded in 2011 by two former Amgen research scientists, Yan Hai and Tom Boone, and is based in Camarillo, CA, with additional facilities in Beijing. REMD Biotherapeutics has established several unique antibody research and development platforms, including a G protein-coupled receptors (GPCRs) antibody platform, a Synermab bispecific antibody platform, and a tumor-activating interferon (TAI) bifunctional antibody interferon fusion platform. The company's most advanced program is volagidemab (REMD-477), a fully human antibody that has completed phase 2 clinical studies in type 1 and type 2 diabetes and is in preparation for initiating multi-center clinical phase 3 studies in type 1 diabetes. | Health Technology |
Ally Bridge Group HK Ltd
![]() Ally Bridge Group HK Ltd Investment ManagersFinance Ally Bridge Group HK Ltd (Ally Bridge) is a private equity firm founded in 2011 by Frank Yu. The firm is headquartered in Hong Kong with additional office in the US. | Finance |